SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.  SK Life Science has announced the availability of Xcopri ...

Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. The Food ...

Last week, the FDA approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. This approval will help offer additional aid for the many individuals throughout the world who live ...

Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently approved XCOPRI for adults with partial-onset seizures, its manufacturer announced. “The ...

Seizures can affect your daily life and well-being. Certain medicines can help lower the risk of having seizures, which can help manage your condition. Fycompa is a medicine used to manage ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

Eisai’s Perampanel is Also Forecasted to Earn Peak Year Sales of up to $250 Million, According to Findings from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the ...

child yellow pill medicine Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line results of a double-blind, placebo-controlled, Phase 3 study evaluating both the 165 mg dose and the 330 mg dose of ...